



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Y. Qui, et al.

Examiner: Not yet assigned

Serial No.: 10/770,290

Group Art Unit: 1615

Filed: February 2, 2004

For: CONTROLLED RELEASE
FORMULATION OF
DIVALPROEX SODIUM

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450 on:

Case No.: 6437.US.C4

Date of Deposit: December 20, 2005

Matthew H. Mader 12/20/05
Matthew H. Mader Date December 20, 2005

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In accordance with their duty of disclosure under 37 C.F.R. §1.56, and as authorized and encouraged under 37 C.F.R. §§ 1.97-1.98 and the provisions of MPEP §§ 609 and 707.05(b), Applicants submit herewith certain patent documents, publications and/or other information ("references") which the Patent and Trademark Office may wish to consider in examining the above-identified patent application. The identification of any reference herein is not intended to be and should not be understood as being an admission that such reference necessarily constitutes "prior art" within the meaning of applicable law.

The Examiner is requested to review and evaluate each cited reference to make an independent assessment of the materiality of each, if any, to the examination of the above-identified application. The Examiner is requested to ignore any underscoring or highlighting which may have been done because such markings may or may not have any relationship to the subject matter of the present invention. The copies being submitted with this Statement are the best copies available at this time. Applicants respectfully request that (1) the references cited herein be made of record; (2) that the Examiner acknowledge his consideration of each reference by initialing and returning the enclosed copy of the PTO-1449 form; and (3) that such references appear on the printed patent as having been considered on the record.

With regard to payment of a fee:

- ☒ No fee is due because:
- ☒ This Statement is mailed within three months of the filing date of this application, or before the mailing date of a first office action on the merits (see 37 C.F.R. §1.97(b)).
- ☐ Applicants certify that each reference cited in this Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement. (see 37 C.F.R. §1.97(e)).
- ☐ This Statement is filed after the mailing date of a first Office Action on the merits but before the mailing date of either a final action or a Notice of Allowance (see 37 C.F.R. §1.97(c)) so a fee of \$180.00 is specified by 37 C.F.R. §1.17(p).

If any fees are owed, or any credit is due pertaining to this case, please charge that fee or apply that credit to Deposit Account No. 01-0025. A duplicate sheet of this page is enclosed.

23492

ABBOTT LABORATORIES
Telephone: (847) 938-3508
Facsimile: (847) 938-2623

Respectfully submitted,
Y. Qui et al.



Paul D. Yasger
Registration No. 37,477
Attorney for Applicants



DATE: December 20, 2005 SHEET _1_ of _1_

Form PTO-1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Modified) PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

6437.US.C4

SERIAL NO.

10/770,290

APPLICANT

Y. Qiu et al.

FILING DATE

February 2, 2004

GROUP

1615

(37 CFR 1.98 (b))

U.S.PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

	DOCUMENT NUMBER	PUBLI- CATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

A1	Dulac et al., "Bioequivalence of a New Sustained-Release Formulation of Sodium Valproate, Valproate Modified-Release Granules, Compared with Existing Sustained-Release Formulations After Once- or Twice-Daily Administration", Pharmacotherapy, 25 (1), 35-41, (2005)
A2	Roberts et al., "Epilim chrono: a multidose, crossover comparison of two formulations of valproate in healthy volunteers", Biopharmaceutics & Drug Disposition, 17 (2), 175-182, (1996)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)